Literature DB >> 22938869

ICUD-EAU International Consultation on Bladder Cancer 2012: Urothelial carcinoma of the prostate.

Juan Palou1, David Wood, Bernard H Bochner, Henk van der Poel, Hikmat A Al-Ahmadie, Ofer Yossepowitch, Mark S Soloway, Lawrence C Jenkins.   

Abstract

CONTEXT: The Second International Consultation on Bladder Cancer recommendations on urothelial carcinoma (UC) of the prostate were presented at the 2011 European Association of Urology Congress in Vienna, Austria, on March 18, 2011.
OBJECTIVE: Our aim is to summarize the Second International Consultation on Bladder Cancer recommendations on UC of the prostate to help clinicians assess the current evidence-based management. EVIDENCE ACQUISITION: The committee performed a thorough review of new data and updated previous recommendations. Levels of evidence and grades of recommendation were assigned based on a systematic review of the literature that included a search of online databases and review articles. EVIDENCE SYNTHESIS: Once a non-muscle-invasive high-grade tumor or carcinoma in situ (CIS) of the bladder has been diagnosed, careful follow-up of the prostatic urethra is necessary. Noninvasive UC including CIS of the prostate should be treated with intravesical bacillus Calmette-Guérin (BCG) following endoscopic resection. A transurethral resection of the prostate may improve contact of BCG with the prostatic urethra, and it appears that response rates to BCG are increased (level of evidence: 3). Transurethral biopsy of the prostatic urethra is effective in identifying prostatic involvement but may not accurately reveal the extent of involvement, particularly with stromal invasion. Stromal invasion by UC of the prostate carries a poor prognosis. Radical cystoprostatectomy is the treatment of choice for locoregional control in patients with prostatic stromal invasion.
CONCLUSIONS: These recommendations contain updated information on the diagnosis and treatment of UC of the prostate. However, prospective trials are needed to further elucidate the best management of these patients.
Copyright © 2012 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22938869     DOI: 10.1016/j.eururo.2012.08.011

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  8 in total

1.  Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer.

Authors:  Aaron Brant; Marcus Daniels; Meera R Chappidi; Gregory A Joice; Nikolai A Sopko; Andres Matoso; Trinity J Bivalacqua; Max Kates
Journal:  World J Urol       Date:  2019-03-08       Impact factor: 4.226

2.  Long-term bowel disorders following radial cystectomy: an underestimated issue?

Authors:  Mario W Kramer; Christoph A von Klot; Mohammad Kabbani; Abdul-Rahman Kabbani; Hossein Tezval; Inga Peters; Thomas R W Herrmann; Markus A Kuczyk; Axel S Merseburger
Journal:  World J Urol       Date:  2015-01-01       Impact factor: 4.226

Review 3.  Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer.

Authors:  Mahul B Amin; Steven C Smith; Victor E Reuter; Jonathan I Epstein; David J Grignon; Donna E Hansel; Oscar Lin; Jesse K McKenney; Rodolfo Montironi; Gladell P Paner; Hikmat A Al-Ahmadie; Ferran Algaba; Syed Ali; Isabel Alvarado-Cabrero; Lukas Bubendorf; Liang Cheng; John C Cheville; Glen Kristiansen; Richard J Cote; Brett Delahunt; John N Eble; Elizabeth M Genega; Christian Gulmann; Arndt Hartmann; Cord Langner; Antonio Lopez-Beltran; Cristina Magi-Galluzzi; Jorda Merce; George J Netto; Esther Oliva; Priya Rao; Jae Y Ro; John R Srigley; Satish K Tickoo; Toyonori Tsuzuki; Saleem A Umar; Theo Van der Kwast; Robert H Young; Mark S Soloway
Journal:  Mod Pathol       Date:  2014-11-21       Impact factor: 7.842

4.  Recommendations for the improvement of bladder cancer quality of care in Canada: A consensus document reviewed and endorsed by Bladder Cancer Canada (BCC), Canadian Urologic Oncology Group (CUOG), and Canadian Urological Association (CUA), December 2015.

Authors:  Wassim Kassouf; Armen Aprikian; Peter Black; Girish Kulkarni; Jonathan Izawa; Libni Eapen; Adrian Fairey; Alan So; Scott North; Ricardo Rendon; Srikala S Sridhar; Tarik Alam; Fadi Brimo; Normand Blais; Chris Booth; Joseph Chin; Peter Chung; Darrel Drachenberg; Yves Fradet; Michael Jewett; Ron Moore; Chris Morash; Bobby Shayegan; Geoffrey Gotto; Neil Fleshner; Fred Saad; D Robert Siemens
Journal:  Can Urol Assoc J       Date:  2016-02-08       Impact factor: 1.862

Review 5.  The mechanism of action of BCG therapy for bladder cancer--a current perspective.

Authors:  Gil Redelman-Sidi; Michael S Glickman; Bernard H Bochner
Journal:  Nat Rev Urol       Date:  2014-02-04       Impact factor: 14.432

Review 6.  Treatment of Urothelial Cancer in Elderly Patients: Focus on Immune Checkpoint Inhibitors.

Authors:  Gray Jodon; Stacy M Fischer; Elizabeth R Kessler
Journal:  Drugs Aging       Date:  2018-05       Impact factor: 3.923

7.  Case report of a primary prostatic urothelial carcinoma patient with sustained fever.

Authors:  Songsong Zhang; Zhenxing Guo
Journal:  Onco Targets Ther       Date:  2018-08-03       Impact factor: 4.147

8.  Alpha-2 Heremans Schmid Glycoprotein (AHSG) promotes the proliferation of bladder cancer cells by regulating the TGF-β signalling pathway.

Authors:  Yufei Dong; Dapeng Ding; Juebin Gu; Mingying Chen; Shijun Li
Journal:  Bioengineered       Date:  2022-06       Impact factor: 6.832

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.